Peptide nucleic acid (PNA) has emerged as a powerhouse in the genetic medicine field due to its unique uncharged peptide-like backbone, which confers extraordinary resistance to enzymatic degradation and superior binding affinity to complementary DNA and RNA. However, the neutral charge of PNA often results in poor aqueous solubility and limited cellular uptake. CD BioGlyco leverages the high-affinity interaction between N-acetylgalactosamine (GalNAc) and the asialoglycoprotein receptor (ASGPR), which is abundantly and specifically expressed on hepatocytes—we provide a robust solution for liver-targeted oligonucleotide delivery. Our platform enables researchers to harness the antisense and antigene potential of PNAs with unprecedented precision, bypassing systemic barriers and maximizing therapeutic efficacy in the liver.
As a core pillar of our therapeutic nucleic acid development platform, CD BioGlyco provides an industry-leading therapeutic oligonucleotide delivery service specifically tailored for GalNAc-PNA constructs. We recognize that the success of a liver-targeted therapy depends not just on the sequence, but on the synergy between the targeting ligand, the chemical linker, and the oligonucleotide backbone. Our service scope is meticulously designed to cover the entire development spectrum, ensuring that your GalNAc-PNA candidates achieve optimal pharmacokinetics and potent gene silencing.
We begin by discussing your target gene and desired biological effect. Our experts assist in PNA sequence design to avoid self-aggregation and maximize hybridization affinity.
Using automated solid-phase synthesis, we assemble the PNA oligomer. We incorporate functional handles (e.g., azides or thiols) at either the 5' or 3' end for subsequent conjugation.
The trivalent GalNAc ligand is synthesized and activated. We conduct rigorous quality control (QC) on the ligand to ensure correct valency and purity.
The activated GalNAc cluster is reacted with the PNA under optimized conditions to ensure high coupling efficiency while minimizing side products.
The crude conjugate undergoes high-performance liquid chromatography (HPLC) to remove unreacted species and truncated sequences, achieving purity levels >95%.
The final product is analyzed via LC-mass spectrometry (LC-MS) to confirm molecular weight and sequence identity. We provide a detailed certificate of analysis (CoA) for every project.
Chronic Viral Hepatitis Research
GalNAc-PNA conjugates are used to target highly conserved regions of the hepatitis B virus (HBV) genome. This allows for the silencing of viral antigens and the inhibition of replication specifically within infected hepatocytes.
Metabolic Disease Modeling
Researchers utilize our delivery service to target genes involved in lipid metabolism. By delivering PNAs to the liver, clients investigate the long-term knockdown of proteins responsible for hypercholesterolemia.
Hepatocellular Carcinoma (HCC) Studies
Targeted delivery of antisense PNAs against oncogenic microRNAs or long non-coding RNAs (lncRNAs) provides a powerful tool for studying tumor suppression and identifying new therapeutic targets in liver cancer.
Rare Genetic Liver Disorders
Our platform supports research into glycogen storage diseases and urea cycle disorders by enabling the delivery of splice-switching PNAs to correct genetic mutations directly at the source.
Unmatched Metabolic Stability
The PNA backbone is completely resistant to nucleases and proteases. When coupled with GalNAc, the resulting conjugate maintains a long half-life in the systemic circulation and intracellular environment.
Enhanced Hybridization Affinity
PNAs form more stable duplexes with RNA than natural DNA or RNA oligonucleotides. This allows for lower dosing regimens while maintaining potent gene silencing or antisense activity.
Reduced Immunogenicity
Unlike lipid nanoparticle (LNP) formulations, GalNAc-PNA conjugates are small, defined chemical entities that typically elicit a much lower innate immune response, allowing for repeated dosing.
Customizable Chemical Linkers
We offer a variety of cleavable and non-cleavable linkers, allowing clients to fine-tune the release of the PNA cargo once internalized within the endo-lysosomal pathway.
"The team at CD BioGlyco provided exceptional support for our HBV research. Their GalNAc-PNA conjugates showed remarkable liver accumulation and potent viral suppression in our mouse models."
– B.F., Metabolic Disease Research
"We struggled with PNA solubility for years until we switched to CD BioGlyco's delivery service. Their tri-antennary GalNAc clusters not only improved targeting but also made the conjugates much easier to work with in aqueous buffers."
– E.M., Biotech Firm
"The LC-MS data provided gave us total confidence in the identity of our therapeutic candidate. CD BioGlyco is our go-to partner for oligonucleotide delivery."
– H.R., Liver Therapeutics Startup
By combining the unrivaled stability of PNA with the exquisite targeting of multivalent GalNAc ligands, CD BioGlyco empowers your research to overcome the traditional barriers of oligonucleotide therapy. Whether you are targeting viral genomes or metabolic regulators, our expertise ensures your project moves from concept to data with speed and accuracy. Please feel free to contact us to discuss your specific sequence requirements and delivery goals.
